CN103282384A - 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法 - Google Patents

复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法 Download PDF

Info

Publication number
CN103282384A
CN103282384A CN201180044500XA CN201180044500A CN103282384A CN 103282384 A CN103282384 A CN 103282384A CN 201180044500X A CN201180044500X A CN 201180044500XA CN 201180044500 A CN201180044500 A CN 201180044500A CN 103282384 A CN103282384 A CN 103282384A
Authority
CN
China
Prior art keywords
leu
pro
gly
antibody
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180044500XA
Other languages
English (en)
Chinese (zh)
Inventor
奥列格·伊里奇·爱泼斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129295/15A external-priority patent/RU2531049C2/ru
Priority claimed from RU2010129294/15A external-priority patent/RU2542414C2/ru
Priority claimed from RU2011127053/15A external-priority patent/RU2565400C2/ru
Application filed by Individual filed Critical Individual
Publication of CN103282384A publication Critical patent/CN103282384A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201180044500XA 2010-07-15 2011-07-15 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法 Pending CN103282384A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
RU2010129294 2010-07-15
RU2010129295 2010-07-15
RU2010129295/15A RU2531049C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2010129294/15A RU2542414C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2011127053 2011-07-01
RU2011127053/15A RU2565400C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы
PCT/IB2011/002417 WO2012007849A2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders

Publications (1)

Publication Number Publication Date
CN103282384A true CN103282384A (zh) 2013-09-04

Family

ID=44899158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180044500XA Pending CN103282384A (zh) 2010-07-15 2011-07-15 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法

Country Status (17)

Country Link
US (1) US20130064860A1 (enExample)
EP (1) EP2593483A2 (enExample)
JP (3) JP2013538791A (enExample)
CN (1) CN103282384A (enExample)
AU (1) AU2011278042B2 (enExample)
CA (1) CA2805094A1 (enExample)
DE (1) DE112011102350T5 (enExample)
EA (1) EA029860B1 (enExample)
ES (1) ES2425314R1 (enExample)
FR (1) FR2962655A1 (enExample)
GB (1) GB2495885B (enExample)
IT (1) ITTO20110631A1 (enExample)
MX (1) MX354187B (enExample)
MY (1) MY165267A (enExample)
NZ (1) NZ606775A (enExample)
SG (2) SG10201505564VA (enExample)
WO (1) WO2012007849A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755599A (zh) * 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2013000543A (es) * 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
FR2962652A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
PH12013500144A1 (en) 2010-07-21 2018-03-21 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
FR2962909A1 (fr) 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055518A1 (fr) * 2001-12-26 2003-07-10 Goldberg, Evgeny Danilovich Procede de traitement d'etats immuno-pathologiques et medicament correspondant
CN101495143A (zh) * 2006-06-06 2009-07-29 奥列格·伊利奇·爱泼斯坦 用于治疗肥胖、糖尿病和与受损的葡萄糖耐受性有关的疾病的药物制剂
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2197266C1 (ru) * 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
CA2577613C (en) * 2004-09-03 2015-12-15 Chr. Hansen A/S Fermented milk or vegetable proteins comprising receptor ligand and uses thereof
MX2008012549A (es) * 2006-04-04 2009-01-14 Dong A Pharm Co Ltd Agente para la prevencion y tratamiento de hiperplasia prostatica que comprende compuesto de pirazolopirimidinona.
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
KR100927958B1 (ko) * 2006-07-13 2009-11-24 주식회사 머젠스 금속의 흡수를 촉진시키는 금속-산성아미노산 킬레이트를함유하는 조성물
MX2013000543A (es) * 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
EA029400B1 (ru) * 2010-07-15 2018-03-30 Олег Ильич ЭПШТЕЙН Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения
MY157564A (en) * 2010-07-15 2016-06-30 Epshtein Oleg Lliich Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome
WO2003055518A1 (fr) * 2001-12-26 2003-07-10 Goldberg, Evgeny Danilovich Procede de traitement d'etats immuno-pathologiques et medicament correspondant
CN101495143A (zh) * 2006-06-06 2009-07-29 奥列格·伊利奇·爱泼斯坦 用于治疗肥胖、糖尿病和与受损的葡萄糖耐受性有关的疾病的药物制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EBI 数据库: "Kallikrein 3, (Prostate specific antigen), isoform CRA_m", 《EBI 数据库》 *
EBI 数据库: "NOS3_BOVIN", 《EBI 数据库》 *
EBI 数据库: "NOS3_HUMAN", 《EBI 数据库》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755599A (zh) * 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物

Also Published As

Publication number Publication date
AU2011278042B2 (en) 2017-02-16
GB2495885B (en) 2017-11-22
ES2425314R1 (es) 2014-07-09
AU2011278042A1 (en) 2013-03-07
JP2018150322A (ja) 2018-09-27
JP2016199570A (ja) 2016-12-01
FR2962655A1 (fr) 2012-01-20
ITTO20110631A1 (it) 2012-01-16
GB201302651D0 (en) 2013-04-03
MY165267A (en) 2018-03-15
WO2012007849A2 (en) 2012-01-19
EP2593483A2 (en) 2013-05-22
JP2013538791A (ja) 2013-10-17
EA029860B1 (ru) 2018-05-31
CA2805094A1 (en) 2012-01-19
DE112011102350T5 (de) 2013-04-18
SG187036A1 (en) 2013-02-28
NZ606775A (en) 2015-08-28
SG10201505564VA (en) 2015-09-29
MX2013000547A (es) 2014-04-14
WO2012007849A3 (en) 2012-04-05
ES2425314A2 (es) 2013-10-14
GB2495885A (en) 2013-04-24
US20130064860A1 (en) 2013-03-14
EA201300129A1 (ru) 2013-12-30
MX354187B (es) 2018-02-16

Similar Documents

Publication Publication Date Title
CN103282384A (zh) 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法
AU2011204349A1 (en) Plasma kallikrein binding proteins
WO2020259605A1 (zh) 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途
EP3687567B1 (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
KR20130060264A (ko) 위장관의 기능적 질환 또는 이상을 치료하는 제약학적 복합 조성물 및 방법들
CN103124742A (zh) 药物组合物和治疗方法
JP2011006464A (ja) 喘息の治療における抗−ＴＮＦα抗体
CN102580086A (zh) 使用抗IL-1α抗体治疗癌症
MX2013000804A (es) Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos.
JP2002538170A5 (enExample)
Song et al. Isoandrographolide inhibits NLRP3 inflammasome activation and attenuates silicosis in mice
JP2011506371A (ja) 抗Ｆａｓリガンド抗体を含有する天疱瘡の治療薬
JP2023507795A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
JP4812748B2 (ja) 自己免疫性疾患および炎症性疾患を処置する方法
RU2651005C2 (ru) Способ повышения фармакологической активности активированной-потенцированной формы антител к простатоспецифическому антигену и фармацевтическая композиция
JP2021526529A (ja) 循環を改善するおよび心血管疾患を治療するための方法
HK40083955A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40120349A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40085254A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40058594A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
CN116063488A (zh) 一种单克隆抗体及其治疗痛风的用途
CN106999579A (zh) 可辨识致病性tdp‑43的抗体及其用途
HK40032645B (zh) 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
CN103108657A (zh) 提高活性强化形式的抗体的效果的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130904

RJ01 Rejection of invention patent application after publication